Vanguard Group Inc Relmada Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,256,705 shares of RLMD stock, worth $364,444. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,256,705
Previous 1,256,705
-0.0%
Holding current value
$364,444
Previous $4.07 Million
83.96%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RLMD
# of Institutions
54Shares Held
8.29MCall Options Held
364KPut Options Held
46.5K-
Franklin Resources Inc San Mateo, CA1.3MShares$377,6230.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$356,0990.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$166,2610.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$143,5920.04% of portfolio
-
Geode Capital Management, LLC Boston, MA303KShares$87,8230.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $8.3M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...